Interaction Checker

Interacciones de Ezetimiba

Ezetimiba (Zetia) tiene 18 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 12; moderadas: 5; leves: 1; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (12)

  • Ácido fenofíbricofibratoGrave

    Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . (etiqueta de Ezetimiba, Interacciones medicamentosas)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • AtorvastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • Ezetimiba y simvastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • FenofibratofibratoGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • FluvastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • GemfibrozilofibratoGrave

    Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1) ] . (etiqueta de Ezetimiba, Interacciones medicamentosas)

  • LovastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • PitavastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • PravastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • RosuvastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

  • SimvastatinaestatinaGrave

    When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. (etiqueta de Ezetimiba, Contraindicaciones)

Interacciones moderadas (5)

  • CiclosporinainmunosupresorModerada

    Table 3: Clinically Important Drug Interactions with ZETIA Cyclosporine Clinical Impact: Concomitant use of ZETIA and cyclosporine increases ezetimibe and cyclosporine concentrations. (etiqueta de Ezetimiba, Interacciones medicamentosas)

  • Colesevelamsecuestrador de ácidos biliaresModerada

    Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (etiqueta de Ezetimiba, Interacciones medicamentosas)

  • Colestipolsecuestrador de ácidos biliaresModerada

    Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (etiqueta de Ezetimiba, Interacciones medicamentosas)

  • Colestiraminasecuestrador de ácidos biliaresModerada

    Bile Acid Sequestrants Clinical Impact: Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. (etiqueta de Ezetimiba, Interacciones medicamentosas)

  • Eltrombopaginhibidor de OATP1B1Moderada

    Transporters Use caution when concomitantly administering ALVAIZ and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP)… (etiqueta de Eltrombopag, Interacciones medicamentosas)

Menciones leves (1)

  • NiacinaLeve

    All participants received simvastatin, 40 to 80 mg per day, plus ezetimibe 10 mg per day if needed, to maintain an LDL-C level of 40-80 mg/dL, and were randomized to receive niacin extended-release tablets 1500-2000 mg/day (n=1718) or matching placebo (IR Niacin, 100-150 mg, n=1696). (etiqueta de Niacina, Advertencias y precauciones)

Compruebe Ezetimiba frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.